Baseline characteristics
hematologic malignancies
HEMATOLOGIC MALIGNANCIES
Eighteen patients were enrolled into the fourth dose study. Median age for this cohort was 69.5 years (IQR 65.5–73.8). Thirty-nine percent (7/18) were seronegative at baseline (after three doses, pre-fourth dose) and 61% patients (11/18) were sero-low (anti-S ab <1000 AU/mL). All patients had hematologic malignancies in this cohort and the breakdown of diagnoses is provided in 